2. Kang Y.K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to or intolerant of at least two previous chemotherapy regimens (ONO-4538-12 ATTRACTION-2): a randomised double-blind placebo-controlled phase 3 trial. Lancet 2017. 390(10111): p. 2461-2471.
3. Fuchs C.S. et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018. 4(5): p. e180013.
4. Mantovani A. et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017. 14(7): p. 399-416.
【CIR | 南京大学魏嘉教授团队揭示胃癌免疫微环境全新调控靶点】5. Pathria P. T.L. Louis and J.A. Varner Targeting Tumor-Associated Macrophages in Cancer. Trends Immunol 2019. 40(4): p. 310-327.
6. Autio K.A. et al. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. Clin Cancer Res 2020. 26(21): p. 5609-5620.
7. Razak A.R. et al. Safety and efficacy of AMG 820 an anti-colony-stimulating factor 1 receptor antibody in combination with pembrolizumab in adults with advanced solid tumors. J Immunother Cancer 2020. 8(2).
8. Zhao R. et al. M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer. Oncoimmunology 2020. 10(1): p. 1862520.
参考消息：https://aacrjournals.org/cancerimmunolres/article-abstract/10/12/1506/711085/DKK1-Promotes-Tumor-Immune-Evasion-and-Impedes?redirectedFrom=fulltext
推荐阅读
- 核酸“匆忙”退场，抗原快速入场，将成为下一个“造富风口”？
- 国家终于出手！多家核酸机构造假被查，张姗姗们恐再难逃惩治！
- 三分钟看懂，中国空间站和国际空间站有哪些不同
- 疫情说没就没了，背后发生了什么？
- 发现“新冠超级免疫者”，他的血液稀释1万倍仍能杀死病毒
- 第7天，我转阴了！确诊女记者的隔离日记
- 地球要进入极寒期？智利拉斯卡尔火山又喷发了，现6000米火山灰柱
- 科尔自欺欺人，雄鹿赢球字母哥输人举动再遭嫌弃，美媒爆4换1交易
- 人类文明能发展到第几等级？距离一级文明，人类文明还差99.28%！